

## Special Issue

# Efficacy, Safety, and Immunogenicity of Hepatitis B Vaccines

### Message from the Guest Editor

There are currently 296 million people living with chronic hepatitis B (HepB) worldwide, and nearly 1 million of these individuals will die each year from disease-related complications. There are multiple hepatitis B vaccines approved for use by international health regulatory agencies, yet the prevalence of HepB continues to rise. This is due, in part, to HepB vaccine non-responsiveness in 5–10% of patients. This issue focuses on efforts to safely improve the efficacy of HepB vaccines by expanding our understanding of non-responsiveness, testing new adjuvants and vectors, and enhancing vaccine stability during transport, with the goal of making the HepB vaccine available and protective to larger numbers of individuals globally.

### Guest Editor

Dr. Benjamin J. Burwitz

Vaccine & Gene Therapy Institute, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR, USA

### Deadline for manuscript submissions

closed (31 December 2023)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/126901](https://mdpi.com/si/126901)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

---

### Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,  
University of Georgia, Athens, GA 30602-7387, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).